Answers are grounded in this paper and cite their sources.
Randomized trial examines immune protein expression in interstitial pneumonia with autoimmune features, suggesting challenges in treatment strategies.
Extract Several of the interstitial lung diseases (ILDs) present a conundrum for clinicians. No group of these conditions is more indicative of this challenge than interstitial pneumonia with autoimmune features (IPAF) [1]. The proposed research classification of IPAF identifies those patients who have serologic, clinical, or radiographic/histologic features of autoimmunity but fail to meet clinical criteria for an autoimmune disease [2]. Recent American College of Rheumatology and Chest ILD guidelines for the treatment of autoimmune ILD recommend first line therapy with immunomodulatory medications for all subsets of autoimmune ILD, though IPAF was notably excluded [3]. Meanwhile, the use of immunomodulatory medications in patients with idiopathic pulmonary fibrosis (IPF) was associated with worsened mortality in a seminal randomized trial [4]. Patients with IPAF do not clearly fit within either of these two poles in ILD management.
No takes yet. Share an insight, caveat, or question.
Ngo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: